Portland, OR -- (SBWIRE) -- 07/19/2017 -- Proteins play a crucial role in maintaining both structural and functional aspects of an individual organism. Long chain of amino acids makes up a protein molecule and regulates all biological functions such as metabolic reactions, DNA replication and other vital expressional functions in the body. Bioengineered proteins are designed as the fundamental participants in all biological processes, represent as powerful therapeutic agents and include a broad range of products such as growth factors, hormones, vaccines, monoclonal antibodies, cytokines and few others. These special drugs are gaining attention across pharmaceutical industries due to their specificity, safety, bioreactivity and success rate in treating life-threatening diseases and injuries. Rising prevalence of diseases such as cancer, diabetes, heart diseases, asthma and others is the crucial driver of the bioengineered protein drugs market.

"Early Buyers Will Receive 20% Customization on This Report."

Other factors propelling the growth of this market include technological advancement in manufacturing bioengineering drug proteins, targeted drug delivery methods for efficient treatment and rising expenditure on healthcare. However, high cost associated with the bioengineered protein drugs limit the growth of the market. Moreover, complications involved while treating certain diseases with bioengineered drugs obstruct the growth of bioengineered protein drugs globally.

Get PDF Brochure @ https://www.alliedmarketresearch.com/request-toc-and-sample/1462

Delivering these biologically active proteins to the target organs and tissues is a major issue. Bioengineered protein drugs are achieving significant progression as novel treatment in number of diseases such as chronic diseases, cancer, asthma and others. Thus, efficient drug delivery methods using technologically advanced vehicles such as micelles, liposomes and hydrogels are contributing toward the growth of this market.

The report segments the bioengineered protein drugs market on the basis of drug types, diseases, technologies, drug delivery methods and geography. On the basis of drug types, the market is further segmented into recombinant protein drugs, peptide hormones, vaccines, therapeutic enzymes, monoclonal antibodies, cytokines, replacement proteins, peptide antibiotics and blood products. Monoclonal antibodies type is the most attractive drug type owing to its increased usage in therapeutics for autoimmune diseases, cancer and inflammatory diseases. According to the diseases segment, the market has been classified into diabetes, cancer, skin diseases, blood disorders, heart diseases, neurodegenerative diseases, respiratory diseases, infectious diseases, congenital diseases, autoimmune disorders, arthritis and others.

Based on technology, the market is further segmented into fractionation, bioreactors and microbial cell fermentation, genetic engineering, genetically modified organisms (GMOs), pharming, bioengineered protein drugs produced by transgenic microorganisms, plants and animals, cell culture and others. The advancement in manufacturing technologies such as GMOs and cell cultures are boosting the market growth. Based on drug delivery methods, the market has been classified into traditional methods and novel approaches. Geographic breakdown and deep analysis of each of the aforesaid segments has been included for North America, Europe, Asia-Pacific and LAMEA. North America dominate the bioengineered protein drugs market and U.S. is the leading country in this market due to the high technological advancements and extensive R&D practiced for manufacturing bioengineered protein drugs.

Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Amgen, Baxter Healthcare, Bayer Healthcare Pharmaceuticals, Eli Lilly and Co., GlaxoSmithKline, Fresenius Kabi USA, Hoffman-la-Roche, Johnson & Johnson and Merck & Co. Inc., have been provided in the report.